MATINS update
Faron Pharmaceuticals Oy ("Faron" or the "Company") MATINS update Second tumour regression identified, now in a melanoma patient Company announcement, 05 March 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that in the ongoing dose finding part of the MATINS trial (Part I) a partial response has been identified in target lesions of a melanoma patient who has previously been heavily treated with immuno-oncology ("IO") and chemo therapies.